## Protocol Section
### Identification Module
**NCT ID:** NCT06436183

**Brief Title:** A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

**Official Title:** A Phase 2a, Multicenter, Randomized, Double-blind, 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

#### Organization Study ID Info
**ID:** AP43CP03
#### Organization
**Class:** INDUSTRY
**Full Name:** Apollo Therapeutics Ltd
### Status Module
#### Completion Date
**Date:** 2025-06

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-30

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-22

**Overall Status:** RECRUITING

#### Primary Completion Date
**Date:** 2025-02

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-05-01

**Type:** ACTUAL

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-30
**Type:** ACTUAL
**Study First Submit Date:** 2024-04-09
**Study First Submit QC Date:** 2024-05-22
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Apollo Therapeutics Ltd

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

### Description Module

**Brief Summary:** This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

**Detailed Description:** This study contains two parts: Parts 1 and Part 2.

Part 1 (Blinded Period):

Eligible patients will be randomized in a 1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2 or placebo.

Part 2 (Extension Period):

In part 2, all participants will receive camoteskimab.

### Conditions Module

**Conditions:**

- Atopic Dermatitis

- Atopic

- Dermatitis

- Dermatologic Disease

- Eczema

- Eczema Atopic Dermatitis

- Eczema, Atopic

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** QUADRUPLE

**Who Masked:**

- PARTICIPANT

- CARE_PROVIDER

- INVESTIGATOR

- OUTCOMES_ASSESSOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 60

**Type:** ESTIMATED

**Phases:**

- PHASE2

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Camoteskimab

**Intervention Names:**

- Drug: Camoteskimab

**Label:** Dose 1

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Camoteskimab

**Intervention Names:**

- Drug: Camoteskimab

- Drug: Placebo

**Label:** Dose 2

**Type:** EXPERIMENTAL

#### Arm Group 3

**Description:** Dummy version of the study drug

**Intervention Names:**

- Drug: Placebo

**Label:** Placebo

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Dose 1

- Dose 2

**Description:** Drug Product

**Name:** Camoteskimab

**Other Names:**

- APL-9109

- AVTX-007

- CERC-007

- AEVI-007

- MEDI2338

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Dose 2

- Placebo

**Description:** Inactive substance

**Name:** Placebo

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** Percentage change from baseline in Eczema Area and Severity Index between camoteskimab and placebo at Week 16

**Measure:** To compare the clinical efficacy of camoteskimab with placebo in participants with AD

**Time Frame:** 16 weeks

#### Secondary Outcomes

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

**Measure:** Percent change from baseline in EASI score at Weeks 2, 4, 8, 12 and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

**Measure:** Change from baseline in EASI score at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

**Measure:** Proportion of participants achieving a 50, 75, 90 and 100% improvement from baseline in EASI (EASI-50, 75, 90 and 100) at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via Investigator's Global Assessment Scale (IGA), which provides a global clinical assessment of AD severity.

**Measure:** Proportion of participants with an IGA 0/1 and a decrease in IGA of ≥ 2 points at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Pruritus Numerical Rating Scale, which assesses itch severity.

**Measure:** Change from baseline in peak pruritus score at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Pruritus Numerical Rating Scale, which assesses itch severity.

**Measure:** Proportion of participants with an improvement of ≥ 4 or more points in peak pruritus weekly score at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Patient-Oriented Eczema Measure (POEM) which assesses disease systems.

**Measure:** Change from baseline in POEM score at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Dermatology Life Quality Index (DLQI) which assesses quality of life.

**Measure:** Change from baseline in DLQI score at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via Body Surface Area (BSA) which assesses the percentage of the total skin affected by AD.

**Measure:** Change from baseline in AD involvement by BSA at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via the Skin Pain Numerical Rating Scale (SP-NRS) which assesses skin pain.

**Measure:** Change from baseline in SP-NRS at Weeks 2, 4, 8, 12, and 16

**Time Frame:** Up to 16 weeks

**Description:** To further assess the efficacy of camoteskimab in participants with AD via Patient Reported Outcomes Measurement Information System (PROMIS) which measures patient-reported health status for physical, mental, and social well-being.

**Measure:** Change from baseline in PROMIS-SRI-SF-8a score at Weeks 2, 4, 8, 12, and 16 reported outcomes

**Time Frame:** Up to 16 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

**Measure:** Percent change from baseline & change from W16 in EASI score at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

**Measure:** Change from baseline & change from W16 in EASI score at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

**Measure:** Proportion of participants achieving a 50, 75, 90 & 100% improvement from baseline line in EASI (EASI-50, 75, 90 & 100) at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via Investigator's Global Assessment Scale (IGA), which provides a global clinical assessment of AD severity.

**Measure:** Proportion of participants with an IGA 0/1 & a decrease in IGA of ≥ 2 points at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Pruritus Numerical Rating Scale, which assesses itch severity.

**Measure:** Change from baseline & change from W16 in peak pruritus score at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Pruritus Numerical Rating Scale, which assesses itch severity.

**Measure:** Proportion of participants with an improvement of ≥ 4 or more points in peak pruritus weekly

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Patient-Oriented Eczema Measure (POEM) which assesses disease systems.

**Measure:** Change from baseline & change from W16 in POEM score at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Dermatology Life Quality Index (DLQI) which assesses quality of life.

**Measure:** Change from baseline & change from W16 in DLQI score at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via Body Surface Area (BSA) which assesses the percentage of the total skin affected by AD.

**Measure:** Change from baseline & change from W16 in AD involvement by BSA at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via the Skin Pain Numerical Rating Scale (SP-NRS) which assesses skin pain.

**Measure:** Change from baseline & change from W16 in SP-NRS at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** To assess the efficacy of extended treatment with camoteskimab in participants with AD via Patient Reported Outcomes Measurement Information System (PROMIS) which measures patient-reported health status for physical, mental, and social well-being.

**Measure:** Change from baseline & change from W16 in PROMIS-SRI-SF-8a score at W20, 24, 28, 32

**Time Frame:** Up to 32 weeks

**Description:** All AEs and SAEs will be collected to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** All AEs and SAEs will be collected from the signing of the ICF until the EOS visit and all SAEs will be collected from the signing of the ICF until 3 months after the last dose of IMP

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** A general PE or symptom directed PE will be performed and abnormalities will be recorded and reported as AEs if appropriate to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** Physical examinations

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** Temperature in Celsius will be measured to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** Vital Signs Assessments - Temperature

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** Systolic and diastolic blood pressure (mmHg) will be measured to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** Vital Signs Assessments - Blood Pressure

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** Pulse (beats/min) will be measured to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** Vital Signs Assessments - Pulse

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** Respiratory rate (breaths/min) will be measured to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** Vital Signs Assessments - Respiratory Rate

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** O2 saturation (%) will be measured to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** Vital Signs Assessments - O2 Saturation

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** PR, QRS, QT, and QTc(F) intervals will be collected to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** ECGs

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** Heart rate will be collected to assess the safety of camoteskimab versus placebo in participants with AD

**Measure:** ECGs - Heart Rate

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** To assess the PK of camoteskimab in participants with AD

**Measure:** PK sampling of unbound camoteskimab in nanograms per milliliter for all participants on Day 1, at Weeks 2 (Day 15), 4 (Day 29), 8 (Day 57), 12 (Day 85), 16 (Day 113), 20 (Day 141), 24 (Day 169), 28 (Day 197), and 32 (Day 225)

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** To assess the PK of camoteskimab in participants with AD

**Measure:** PK Total LCMS sampling in ng/mL to determine camoteskimab exposures in the body over time for all participants on Day 1, at Weeks 2 (Day 15), 4 (Day 29), 8 (Day 57), 12 (Day 85), 16 (Day 113), 20 (Day 141), 24 (Day 169), 28 (Day 197), and 32 (Day 225)

**Time Frame:** Through study completion, an average of 36 weeks

**Description:** To assess the PK of camoteskimab in participants with AD

**Measure:** PK Total Immunoassay sampling (sum of bound and free) in ng/mL for all participants on Day 1, at Weeks 2 (Day 15), 4 (Day 29), 8 (Day 57), 12 (Day 85), 16 (Day 113), 20 (Day 141), 24 (Day 169), 28 (Day 197), and 32 (Day 225)

**Time Frame:** Through study completion, an average of 36 weeks

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

1. Participants must be 18-75 years of age inclusive, at the time of signing the informed consent.
2. Chronic AD for at least 1 year.
3. Participants with moderate to severe AD defined by:

   1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Baseline.
   2. AD involvement of ≥ 10% body surface area (BSA) at Baseline.
   3. EASI score of ≥ 12 at Baseline.
   4. Pruritus numerical rating scale (NRS) ≥ 4 at Baseline.
4. Participants who are candidates for systemic therapy, defined as inadequate response to treatment with topical medications, or for whom topical treatments are otherwise medically inadvisable.
5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

   Female participants:
   * Sexually active females of childbearing potential must agree to use two forms of accepted methods of highly effective forms of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:
   * IUD plus one barrier method.
   * Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method.
   * 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or
   * A vasectomized partner\*.

   Male participants:
   * Sexually active male participants and males and who are partners of females of childbearing potential agree to use two forms of contraception as above and to not donate sperm or try to conceive during the treatment period and for at least 3 months after the last dose of study drug.
6. Participant provides signed informed consent.

Exclusion Criteria:

1. Participant has history of use of more than two (2) prior systemic therapies for AD (e.g.

   biologics or JAKi) and who used any of these medications as follows:
   1. Dupilumab, tralokinumab, lebrikizumab within 8 weeks prior to Baseline.
   2. Systemic JAKi within 4 weeks prior to Baseline.
   3. TCS, TCI, topical phosphodiesterase-4 (PDE4) inhibitors, and topical JAKi within 7 days prior to enrollment (at Baseline) or more than five half-lives whichever is longer.
2. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments.
3. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma).
4. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12- lead ECG as considered by the perfusion index that may interfere with the interpretation of QTc interval changes.
5. Participant has AD involving ocular symptoms, or blepharitis, conjunctivitis, or keratitis diagnosed within the last 60 days prior to the screening visit, requiring chronic ocular corticosteroid treatment.
6. Participant has severe or uncontrolled seasonal or allergic rhinitis, asthma or any other non-AD disease as judged by the Investigator. Participants with seasonal or allergic rhinitis, asthma or any other non-AD disease requiring use of intranasal or inhaled corticosteroid that is stable and well-controlled are not excluded.
7. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test; Active hepatitis B virus (HBV): confirmed hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+); Active hepatitis C virus (HCV): Confirmed hepatitis C antibody positive (+); evidence of active or latent TB
8. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of

   * Completely resected basal call or squamous cell carcinoma of the skin.
   * Carcinoma in situ of the cervix.
9. Has had previous exposure to anti-IL-18 therapy.
10. Treatment with any investigational agent, or any investigational device or procedure, within 28 days (or 5 half- lives, whichever is greater) of screening.
11. Has any of the following laboratory findings

    1. Glomerular filtration rate (GFR) \< 30 mL/min/1.73 m2.
    2. Hemoglobin ≤8 g/dL.
    3. Neutrophils ≤1,500/μL.
    4. Platelets ≤75,000/μL.

**Maximum Age:** 75 Years

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** AP43@apollotx.com

**Name:** Apollo Therapeutics

**Phone:** +1 781 479 2267

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Phoenix

**Contacts:**

***Contact 1:***

- **Name:** Lindsay Ackerman

- **Role:** CONTACT

**Country:** United States

**Facility:** Medical Dermatology Specialists, PC/US Dermatology Partners

**State:** Arizona

**Status:** NOT_YET_RECRUITING

**Zip:** 85006

**Location 2:**

**City:** Encinitas

**Contacts:**

***Contact 1:***

- **Name:** Stacy Smith

- **Role:** CONTACT

**Country:** United States

**Facility:** California Dermatology & Clinical Research Institute

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 92024

**Location 3:**

**City:** Los Angeles

**Contacts:**

***Contact 1:***

- **Name:** Ricardo Tan

- **Role:** CONTACT

**Country:** United States

**Facility:** California Allergy and Asthma Medical Group

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 90025

**Location 4:**

**City:** Los Angeles

**Contacts:**

***Contact 1:***

- **Name:** April Armstrong

- **Role:** CONTACT

**Country:** United States

**Facility:** Keck School of Medicine of USC

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 90095

**Location 5:**

**City:** San Diego

**Contacts:**

***Contact 1:***

- **Name:** Henry Wong

- **Role:** CONTACT

**Country:** United States

**Facility:** VASDHS - Veterans Affairs San Diego Medical Center

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 92161

**Location 6:**

**City:** Fort Myers

**Contacts:**

***Contact 1:***

- **Name:** Alfonso Garcio-Bello

- **Role:** CONTACT

**Country:** United States

**Facility:** Floridian Research Institute, Llc

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 33901

**Location 7:**

**City:** Miami

**Contacts:**

***Contact 1:***

- **Name:** Brent Schillinger

- **Role:** CONTACT

**Country:** United States

**Facility:** D&H National Research Centers, Inc.

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 33155

**Location 8:**

**City:** Tampa

**Contacts:**

***Contact 1:***

- **Name:** Thomas Taylor

- **Role:** CONTACT

**Country:** United States

**Facility:** GCP Clinical Research

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 33613

**Location 9:**

**City:** Normal

**Contacts:**

***Contact 1:***

- **Name:** Dareen Siri

- **Role:** CONTACT

**Country:** United States

**Facility:** Sneeze, Wheeze & Itch Associates, LLC

**State:** Illinois

**Status:** NOT_YET_RECRUITING

**Zip:** 61761

**Location 10:**

**City:** Indianapolis

**Contacts:**

***Contact 1:***

- **Name:** Scott Fretzin

- **Role:** CONTACT

**Country:** United States

**Facility:** Dawes Fretzin Clinical Research

**State:** Indiana

**Status:** NOT_YET_RECRUITING

**Zip:** 46250

**Location 11:**

**City:** Louisville

**Contacts:**

***Contact 1:***

- **Name:** Leon Kircik

- **Role:** CONTACT

**Country:** United States

**Facility:** Skin Sciences, Pllc

**State:** Kentucky

**Status:** NOT_YET_RECRUITING

**Zip:** 40217

**Location 12:**

**City:** Owensboro

**Contacts:**

***Contact 1:***

- **Name:** Artis Truett

- **Role:** CONTACT

**Country:** United States

**Facility:** Owensboro Dermatology Associates

**State:** Kentucky

**Status:** RECRUITING

**Zip:** 42303

**Location 13:**

**City:** Troy

**Contacts:**

***Contact 1:***

- **Name:** George Murakawa

- **Role:** CONTACT

**Country:** United States

**Facility:** Somerset Skin Centre

**State:** Michigan

**Status:** NOT_YET_RECRUITING

**Zip:** 48084

**Location 14:**

**City:** Saint Joseph

**Contacts:**

***Contact 1:***

- **Name:** Melody Stone

- **Role:** CONTACT

**Country:** United States

**Facility:** Advanced Dermatology and Skin Cancer Center - Saint Joseph

**State:** Missouri

**Status:** NOT_YET_RECRUITING

**Zip:** 64506

**Location 15:**

**City:** Omaha

**Contacts:**

***Contact 1:***

- **Name:** Joel Schlessinger

- **Role:** CONTACT

**Country:** United States

**Facility:** Skin Specialists PC

**State:** Nebraska

**Status:** RECRUITING

**Zip:** 68144

**Location 16:**

**City:** Raleigh

**Contacts:**

***Contact 1:***

- **Name:** David Ginsberg

- **Role:** CONTACT

**Country:** United States

**Facility:** M3 Wake Research, Inc.

**State:** North Carolina

**Status:** NOT_YET_RECRUITING

**Zip:** 27612

**Location 17:**

**City:** Cleveland

**Contacts:**

***Contact 1:***

- **Name:** Neil Korman

- **Role:** CONTACT

**Country:** United States

**Facility:** University Hospitals Case Medical Center

**State:** Ohio

**Status:** NOT_YET_RECRUITING

**Zip:** 44106

**Location 18:**

**City:** Oklahoma City

**Contacts:**

***Contact 1:***

- **Name:** Yaohan Lam

- **Role:** CONTACT

**Country:** United States

**Facility:** Central Sooner Research

**State:** Oklahoma

**Status:** NOT_YET_RECRUITING

**Zip:** 73071

**Location 19:**

**City:** Philadelphia

**Contacts:**

***Contact 1:***

- **Name:** Lawrence Parish

- **Role:** CONTACT

**Country:** United States

**Facility:** Paddington Testing Co. Inc

**State:** Pennsylvania

**Status:** RECRUITING

**Zip:** 19103

**Location 20:**

**City:** Frisco

**Contacts:**

***Contact 1:***

- **Name:** Timothy Rodgers

- **Role:** CONTACT

**Country:** United States

**Facility:** Rodgers Dermatology

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 75034

**Location 21:**

**City:** Houston

**Contacts:**

***Contact 1:***

- **Name:** Stephen Tyring

- **Role:** CONTACT

**Country:** United States

**Facility:** Center for Clinical Studies

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 77004

**Location 22:**

**City:** Houston

**Contacts:**

***Contact 1:***

- **Name:** Mushtaq Khan

- **Role:** CONTACT

**Country:** United States

**Facility:** Clinical Trial Network

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 77074

**Location 23:**

**City:** Edmonton

**Contacts:**

***Contact 1:***

- **Name:** Mariusz Joseph Albert Sapijaszko

- **Role:** CONTACT

**Country:** Canada

**Facility:** Youthful Image

**State:** Alberta

**Status:** NOT_YET_RECRUITING

**Zip:** T5J 3S9

**Location 24:**

**City:** Edmonton

**Contacts:**

***Contact 1:***

- **Name:** Matthew Karpman

- **Role:** CONTACT

**Country:** Canada

**Facility:** Rejuvenation Dermatology Clinic Edmonton South

**State:** Alberta

**Status:** NOT_YET_RECRUITING

**Zip:** T6W 0J5

**Location 25:**

**City:** Etobicoke

**Contacts:**

***Contact 1:***

- **Name:** Marnie Fisher

- **Role:** CONTACT

**Country:** Canada

**Facility:** Kingsway Clinical Research

**State:** Ontario

**Status:** NOT_YET_RECRUITING

**Zip:** M8X 1Y9

**Location 26:**

**City:** Ottawa

**Contacts:**

***Contact 1:***

- **Name:** William Yang

- **Role:** CONTACT

**Country:** Canada

**Facility:** Ottawa Allergy Research Corporation

**State:** Ontario

**Status:** NOT_YET_RECRUITING

**Zip:** K1H 1E4

**Location 27:**

**City:** Québec

**Contacts:**

***Contact 1:***

- **Name:** Virginie Kelly

- **Role:** CONTACT

**Country:** Canada

**Facility:** Clinique Medicale Saint-Louis

**State:** Quebec

**Status:** NOT_YET_RECRUITING

**Zip:** G1W 4R4

**Location 28:**

**City:** Sherbrooke

**Contacts:**

***Contact 1:***

- **Name:** Evelyn Chinchilla

- **Role:** CONTACT

**Country:** Canada

**Facility:** Clinique Dermatologique de Sherbrooke

**State:** Quebec

**Status:** NOT_YET_RECRUITING

**Zip:** J1G 1X9

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000012873

- Term: Skin Diseases, Genetic

- ID: D000030342

- Term: Genetic Diseases, Inborn

- ID: D000017443

- Term: Skin Diseases, Eczematous

- ID: D000006969

- Term: Hypersensitivity, Immediate

- ID: D000006967

- Term: Hypersensitivity

- ID: D000007154

- Term: Immune System Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC17

- Name: Skin and Connective Tissue Diseases

- Abbrev: All

- Name: All Conditions

- Abbrev: BC16

- Name: Diseases and Abnormalities at or Before Birth

- Abbrev: BC20

- Name: Immune System Diseases

### Condition Browse Module - Browse Leaves

- ID: M7067

- Name: Dermatitis

- Relevance: HIGH

- As Found: Dermatitis

- ID: M7071

- Name: Dermatitis, Atopic

- Relevance: HIGH

- As Found: Atopic Dermatitis

- ID: M7655

- Name: Eczema

- Relevance: HIGH

- As Found: Atopic Dermatitis

- ID: M15674

- Name: Skin Diseases

- Relevance: HIGH

- As Found: Dermatologic Disease

- ID: M15676

- Name: Skin Diseases, Genetic

- Relevance: LOW

- As Found: Unknown

- ID: M23686

- Name: Genetic Diseases, Inborn

- Relevance: LOW

- As Found: Unknown

- ID: M19712

- Name: Skin Diseases, Eczematous

- Relevance: LOW

- As Found: Unknown

- ID: M10018

- Name: Hypersensitivity

- Relevance: LOW

- As Found: Unknown

- ID: M10020

- Name: Hypersensitivity, Immediate

- Relevance: LOW

- As Found: Unknown

- ID: M10200

- Name: Immune System Diseases

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000003876

- Term: Dermatitis, Atopic

- ID: D000003872

- Term: Dermatitis

- ID: D000004485

- Term: Eczema

- ID: D000012871

- Term: Skin Diseases

### Misc Info Module

- Version Holder: 2024-05-31
